Commentary on the "Co-Crystal of Tramadol-Celecoxib in Patients with Moderate to Severe Acute Post-Surgical Oral Pain: A Dose-Finding, Randomised, Double-Blind, Placebo- and Active-Controlled, Multicentre Phase II Trial". Implications for Cardiovascular Safety

Sebastián Videla; Neus Gascón; Carlos Plata-Salamán

doi:10.29245/2578-3025/2019/1.1163

Commentary on the "Co-Crystal of Tramadol-Celecoxib in Patients with Moderate to Severe Acute Post-Surgical Oral Pain: A Dose-Finding, Randomised, Double-Blind, Placebo- and Active-Controlled, Multicentre Phase II Trial". Implications for Cardiovascular Safety

Journal of Cardiology and Cardiovascular Sciences ◽

10.29245/2578-3025/2019/1.1163 ◽

2019 ◽

Vol 3 (1) ◽

pp. 1-3

Author(s):

Sebastián Videla ◽

Neus Gascón ◽

Carlos Plata-Salamán

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Dose Finding ◽

Cardiovascular Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Multicentre Phase ◽

Oral Pain

Download Full-text

Commentary on the "Co-Crystal of Tramadol-Celecoxib in Patients with Moderate to Severe Acute Post-Surgical Oral Pain: A Dose-Finding, Randomised, Double-Blind, Placebo- and Active-Controlled, Multicentre Phase II Trial". Implications for Cardiovascular Safety

Journal of Cardiology and Cardiovascular Sciences ◽

10.29245/2578-3025/2018/1.1163 ◽

2019 ◽

Vol 3 (1) ◽

pp. 1-3

Author(s):

Sebastián Videla ◽

Neus Gascón ◽

Carlos Plata-Salamán

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Dose Finding ◽

Cardiovascular Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Multicentre Phase ◽

Oral Pain

Download Full-text

Co-crystal of Tramadol–Celecoxib in Patients with Moderate to Severe Acute Post-surgical Oral Pain: A Dose-Finding, Randomised, Double-Blind, Placebo- and Active-Controlled, Multicentre, Phase II Trial

Drugs in R&D ◽

10.1007/s40268-018-0235-y ◽

2018 ◽

Vol 18 (2) ◽

pp. 137-148 ◽

Cited By ~ 6

Author(s):

José López-Cedrún ◽

◽

Sebastián Videla ◽

Miguel Burgueño ◽

Inma Juárez ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Dose Finding ◽

Double Blind ◽

Double Blind Placebo ◽

Multicentre Phase ◽

Oral Pain

Download Full-text

A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)

European Journal of Cancer ◽

10.1016/j.ejca.2015.10.012 ◽

2016 ◽

Vol 53 ◽

pp. 144-154 ◽

Cited By ~ 19

Author(s):

Konstantinos Tryfonidis ◽

Gul Basaran ◽

Jan Bogaerts ◽

Marc Debled ◽

Luc Dirix ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Multicentre Phase ◽

European Organisation ◽

Hormone Receptor Positive

Download Full-text

Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme

European Journal of Cancer ◽

10.1016/j.ejca.2014.09.013 ◽

2014 ◽

Vol 50 (18) ◽

pp. 3125-3135 ◽

Cited By ~ 68

Author(s):

M. Moehler ◽

A. Maderer ◽

C. Schimanski ◽

S. Kanzler ◽

U. Denzer ◽

...

Keyword(s):

Biliary Tract ◽

Phase Ii ◽

Biliary Tract Cancer ◽

Double Blind ◽

Double Blind Placebo ◽

Multicentre Phase ◽

Tract Cancer

Download Full-text

Study Protocol for a Randomized, Double-Blind, Placebo-Controlled, Phase-II Trial: AdrenoMedullin for Ischemic Stroke Study

Journal of Stroke and Cerebrovascular Diseases ◽

10.1016/j.jstrokecerebrovasdis.2021.105761 ◽

2021 ◽

Vol 30 (6) ◽

pp. 105761

Author(s):

Takeshi Yoshimoto ◽

Satoshi Saito ◽

Katsuhiro Omae ◽

Yorito Hattori ◽

Kazuki Fukuma ◽

...

Keyword(s):

Ischemic Stroke ◽

Phase Ii ◽

Study Protocol ◽

Phase Ii Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Stroke Study

Download Full-text

Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU)

Acta Dermato Venereologica ◽

10.2340/00015555-3120 ◽

2019 ◽

Vol 99 (4) ◽

pp. 379-385 ◽

Cited By ~ 19

Author(s):

A Tsianakas ◽

C Zeidler ◽

C Riepe ◽

M Borowski ◽

C Forner ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Early Survival of Comatose Patients after Severe Traumatic Brain Injury with the Dual Cannabinoid CB1/CB2 Receptor Agonist KN38-7271: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial

Journal of Neurological Surgery Part A Central European Neurosurgery ◽

10.1055/s-0032-1304815 ◽

2012 ◽

Vol 73 (04) ◽

pp. 204-216 ◽

Cited By ~ 7

Author(s):

Raimund Firsching ◽

Jürgen Piek ◽

Martin Skalej ◽

Veit Rohde ◽

Uwe Schmidt ◽

...

Keyword(s):

Traumatic Brain Injury ◽

Brain Injury ◽

Phase Ii ◽

Severe Traumatic Brain Injury ◽

Receptor Agonist ◽

Phase Ii Trial ◽

Cb2 Receptor ◽

Double Blind ◽

Double Blind Placebo ◽

Early Survival

Download Full-text

Abstract P2-08-19: Exploratory biomarker analyses of FAIRLANE, a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (TNBC)

10.1158/1538-7445.sabcs18-p2-08-19 ◽

2019 ◽

Author(s):

MJ Wongchenko ◽

M Oliveira ◽

C Saura ◽

P Nuciforo ◽

I Calvo ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase Ii Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Randomized Phase Ii

Download Full-text

Oltipraz therapy in patients with liver fibrosis or cirrhosis: a randomized, double-blind, placebo-controlled phase II trial

Journal of Pharmacy and Pharmacology ◽

10.1111/j.2042-7158.2011.01259.x ◽

2011 ◽

Vol 63 (5) ◽

pp. 627-635 ◽

Cited By ~ 16

Author(s):

Sang Geon Kim ◽

Young Mi Kim ◽

Jong Young Choi ◽

Joon-Yeol Han ◽

Jeong Won Jang ◽

...

Keyword(s):

Liver Fibrosis ◽

Phase Ii ◽

Phase Ii Trial ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Mo1945 Intragastric Injection of Botulinum Toxin a to Treat Obesity: Mechanism of Action and a Randomized, Double-Blind, Placebo-Controlled Phase II Trial With Open-Label Extension Study

Gastroenterology ◽

10.1016/s0016-5085(16)32787-1 ◽

2016 ◽

Vol 150 (4) ◽

pp. S823

Author(s):

Duan Chen ◽

Magnus K. Olsen ◽

Magnus Strommen ◽

Helene Johannessen ◽

Hege T. Bjoru ◽

...

Keyword(s):

Botulinum Toxin ◽

Phase Ii ◽

Mechanism Of Action ◽

Phase Ii Trial ◽

Botulinum Toxin A ◽

Open Label ◽

Toxin A ◽

Double Blind ◽

Double Blind Placebo ◽

Open Label Extension

Download Full-text